[A23-59] Nivolumab (melanoma in adolescents, adjuvant) – Benefit assessment according to §35a Social Code Book V
Last updated 02.10.2023
Commission awarded on 30.06.2023 by the Federal Joint Committee (G-BA).
Monotherapy for the adjuvant treatment of adolescents 12 years of age and older with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection
- Tumour stage III (involvement of lymph nodes): added benefit not proven
- Tumour stage IV (metastatic disease): added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.